DrugPatentWatch Database Preview
Drugs in Development Information for Aldoxorubicin
What is the development status for investigational drug Aldoxorubicin?
Aldoxorubicin is an investigational drug.
There have been 16 clinical trials for Aldoxorubicin.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2014.
The most common disease conditions in clinical trials are Sarcoma, Lung Neoplasms, and Pancreatic Neoplasms. The leading clinical trial sponsors are CytRx, NantKwest, Inc., and [disabled in preview].
There are two US patents protecting this investigational drug and ten international patents.
Summary for Aldoxorubicin
US Patents | 2 |
International Patents | 10 |
US Patent Applications | 8 |
WIPO Patent Applications | 0 |
Japanese Patent Applications | 0 |
Clinical Trial Progress | Phase 2 (2014-01-01) |
Vendors | 15 |
Recent Clinical Trials for Aldoxorubicin
Title | Sponsor | Phase |
---|---|---|
QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | NantKwest, Inc. | Phase 2 |
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer | NantKwest, Inc. | Phase 2 |
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. | NantKwest, Inc. | Phase 1/Phase 2 |
Clinical Trial Summary for Aldoxorubicin
Top disease conditions for Aldoxorubicin
Top clinical trial sponsors for Aldoxorubicin
US Patents for Aldoxorubicin
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Aldoxorubicin | Start Trial | Anthracycline formulations | CytRx Corporation (Los Angeles, CA) | Start Trial |
Aldoxorubicin | Start Trial | Combinations of albumin-based drug delivery systems | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | Start Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Aldoxorubicin
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Aldoxorubicin | Australia | 2013359048 | 2032-12-13 | Start Trial |
Aldoxorubicin | Canada | 2894548 | 2032-12-13 | Start Trial |
Aldoxorubicin | European Patent Office | 2931042 | 2032-12-13 | Start Trial |
Aldoxorubicin | Hong Kong | 1209973 | 2032-12-13 | Start Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |